Company news
Cg Oncology, Inc. (NASDAQ:CGON) news
Cg Oncology, Inc. news releases on 6ix. Latest, May 3, 2024: Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk…
Press releases — page 2
Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
May 2, 2024
CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024
April 25, 2024
CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024
April 23, 2024
CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting
March 27, 2024
CG Oncology Announces First Patient Dosed in PIVOT-006 Phase 3 Clinical Trial of Cretostimogene in Intermediate-risk Non-Muscle Invasive Bladder Cancer
February 26, 2024
CG Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
January 29, 2024
CG Oncology Announces Pricing of Upsized Initial Public Offering
January 23, 2024